Show simple item record

dc.creatorPadayatchi, Nesri.
dc.creatorFriedland, Gerald H.
dc.date.accessioned2013-05-21T10:26:25Z
dc.date.available2013-05-21T10:26:25Z
dc.date.created2007
dc.date.issued2007
dc.identifier.citationPadayatchi, N., Friedland, G. 2007. Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opin. Pharmacother. 8(8) pp. 1035-1037.en
dc.identifier.issn1465-6566
dc.identifier.urihttp://dx.doi.org/10.1517/14656566.8.8.1035en
dc.identifier.urihttp://hdl.handle.net/10413/8948
dc.description.abstractGlobal increases in multi-drug-resistant and extensively drug-resistant tuberculosis (TB), are threatening both TB and HIV treatment programs worldwide. Together, they raise concerns of a global epidemic of untreatable TB. In the developing world, the directly observed treatment, short course (DOTS) strategy is proving ineffective as available resources are being outstripped by the large number of patients needing treatment. Thus, TB treatment and outcomes are sub-optimal, and multi-drug resistant and extensively drug-resistant TB are on the rise.en
dc.language.isoenen
dc.publisherInforma Healthcare.en
dc.subjectMultidrug-resistant tuberculosis.en
dc.subjectMultidrug-resistant tuberculosis--Treatment.en
dc.subjectHIV infections--Treatment.en
dc.subjectDirectly observed therapy (Program)en
dc.subject.otherMDR-TB.en
dc.subject.otherXDR-TB.en
dc.subject.otherExtensively drug-resistant tuberculosis.en
dc.subject.otherTuberculosis directly observed therapy.en
dc.subject.otherDOTS.en
dc.titleManaging multiple and extensively drug-resistant tuberculosis and HIV.en
dc.typePeer reviewed journal articleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record